kisspeptin peptide: Frequently asked questions

That's expected. Standard immunoassays for kisspeptin have detection limits around 0.5–1.0 picomoles per liter, and plasma concentrations fall below this threshold within 90–150 minutes after a single bolus dose. If you're tracking kisspeptin clearance kinetics, you need samples collected at 5, 15, 30, 60, and 90 minutes post-injection. By 120 minutes, the peptide is gone. If your protocol requires proof of circulating kisspeptin at later timepoints, you'd need either a more sensitive assay (mass spectrometry-based methods detect down to 0.1 pmol/L) or repeated dosing to maintain measurable levels.

Switch to continuous intravenous infusion rather than bolus dosing. Infusion rates of 0.01–0.1 micrograms per kilogram per minute maintain steady-state plasma concentrations without the peak-and-trough pattern of bolus administration. This approach is used in studies investigating sustained GnRH receptor activation, but it sacrifices the pulsatile pattern that reflects endogenous kisspeptin signaling. If your research question requires pulsatility, continuous infusion isn't appropriate. Repeated bolus dosing every 60–90 minutes is the correct protocol.

Consider kisspeptin-54 or a modified analog, but understand the trade-offs. Kisspeptin-54 buys you an additional 10–15 minutes of circulating peptide, which may be enough to extend your measurement window without moving to synthetic analogs. PEGylated kisspeptin analogs extend half-life to several hours but introduce non-physiological receptor kinetics. If your goal is to model natural reproductive physiology, the short half-life isn't a limitation. It's the feature that makes kisspeptin accurate. Extending clearance for convenience often compromises the biological relevance of the results.

Both are kisspeptin. The number indicates the amino acid length of the specific isoform used. Kisspeptin-10 is the shortest active fragment (10 amino acids), while kisspeptin-54 is the full-length mature peptide cleaved from the KISS1 precursor. All isoforms share the same C-terminal decapeptide that drives receptor binding, so biological activity is equivalent at equimolar doses. The choice depends on study design: kisspeptin-10 is easier to synthesize and more stable in solution, while kisspeptin-54 has a longer in vivo half-life (28 minutes vs 4 minutes), making it better suited for sustained signaling studies. Neither is 'better'. They're the same signaling molecule at different fragment lengths.

The most common cause is peptide degradation from improper storage or reconstitution. Kisspeptin is highly susceptible to proteolytic cleavage by serum peptidases. If the lyophilized powder was stored above −20°C or the reconstituted solution wasn't used within 48 hours, bioactivity drops precipitously even if the solution appears clear. Verify purity via mass spectrometry and HPLC before assuming the assay conditions are at fault. Secondary causes include incorrect receptor expression in the cell line (KISS1R must be present at sufficient density) or serum interference in the assay medium. Kisspeptin degrades rapidly in the presence of proteases, so assays should use serum-free medium or include protease inhibitors.

Metastin is the original name given to kisspeptin-54 when it was first identified as a metastasis suppressor in melanoma cells in 1996. The reproductive function wasn't discovered until 2003, at which point the molecule was renamed kisspeptin to reflect its role in reproductive physiology. Both names refer to the same 54-amino-acid peptide. Current literature uses 'kisspeptin' almost exclusively, but older papers (pre-2005) and some cancer research still use 'metastin.' If you encounter metastin in a protocol, it's referring to kisspeptin-54. Treat dosing and handling identically.